On Monday, the US Food and Drug Administration approved Cyramza to treat stomach cancer or the area where the esophagus joins the stomach, known as the gastroesophageal junction.
In a news release on Monday, the FDA mentioned that stomach cancer which usually affects older people is expected to be diagnosed in as many as 22,000 American people this year. Moreover, it is also anticipated that around 10,990 people will die because of it.
The drug functions by stopping the blood supply to tumors. The agency said that the drug has been approved for such advanced cases where it is not possible to remove the tumor surgically or in cases where the cancer has spread despite the use of anti-cancer drugs.
The safety and effectiveness of cyramza were analyzed in clinical studies involving around 355 people. According to FDA, the people who were given the drug lived for 5.2 months on average, compared to those people who got a placebo and lived for 3.8 months.
As for the side effects, high blood pressure and diarrhea are the common ones observed.
The marketing of Cyramza is being done by Eli Lilly, based in Indianapolis.